Editorial

Drug-Induced Systemic Erythematosus in Childhood
It was not until the recognition of the lupus erythematosus cell that drug-related systemic lupus erythematosus (SLE) started to be described, with hydralazine providing the basis for the first accepted report. Since then various groups of drugs have been incriminated', but in childhood the most common association has been with anticonvulsant therapy3.4 particularly with administration of diphenyl hydantoin, mephenytoin, trimethadione and ethosuximide'. It has also been reported with carbimazole'. It has occasionally been recorded after treatment with hydralazine', while it has been seen after the use of sulphazalazine in ulcerative colitis' and Crohn's disease9. Other drugs that have been implicated include the oral contraceptive pill, sulphonamides, isoniazid&dquo;, sulphasalazine and penicillamine used in juvenile arthritis as well as griseofulvin used in generalized fungal infections and propylthiouracil used for hyperthyroidism 10.
With anticonvulsants of different types most commonly implicated, it has been suggested that perhaps the seizures were the first symptom of spontaneous SLE and not the result of anticonvulsant therapy. However Beernik and Miller3 reviewed 48 children receiving anticonvulsant therapy in a paediatric neurology clinic at Stanford University between 1968 and 1971 and noted that, while 11 I children had antinuclear antibodies (ANA) all of these patients were asymptomatic; they also reported five patients with ANA and lupus-like symptoms. The cause of fits in these 16 children were as follows: four had had developmental retardation in infancy; five had had specific events associated with the onset of seizures; one was normal; and only six had had post-infancy onset of seizures of truly idiopathic type. The presence or absence of lupus-like symptoms did not correlate with the cause of the seizures. Four of the five symptomatic children who were switched to drugs other than hydantoin, trimethadione or ethosuximide had remission of their lupus s ptomsp one contiued to have persistent neuropenia but no renal involvment. The 1I I asymptomatic patients with positive ANA were maintained on their ususal anticonvulsant therapy without change, and only one has developed any symptoms suggestive of lupus~°. Thus, this experience supports the concept that anticonvulsants do have a lupus-inducing potential.
In general the American Rheumatism Association's criteria for classification of SLE are appropriate for these patients. There are some differences: boys appear to be affected almost as commonly as girls and there is rarely renal involvement. The rash may be a typical malar one, but others such as urticaria, a rash resembling juvenile chronic arthiristis, Stevens-Johnson syndrome, and even something looking like scleroderma but with the histology of lupus have been recorded&dquo;. The disease appears to be relatively short lived once the drug is removed, although at times the child will be severely ill, requiring corticosteriod therapy. Very occasionally renal involvement does occur and then the course appears to be that of true lupus. Death has been recorded as a result of renal disease. As yet typical central nervous system lupus has not been seen, but it must be remembered that occasionally fits can antedate SLE. There appears to be no information as to whether lupus induced by anticonvulsant drugs is more likely in slow acetylators, nor have there been any studies of the HLA system, although a family history of different rheumatic diseases does seem to occur more frequently in these patients than in controls. That anticonvulsant drugs are important is supported. by the work of Singsen and his colleagues', who noted that 14 of 70 patients on known anticonvulsant inducers had high titres of ANA compared with low titres in five of 23 phenobarbitone and one of 50 controls, all without symptoms. They also reported five children referred to them who presented with a syndrome mimicking SLE while they were receiving ethosuximide. All had fever, malaise, rashes, arthritis (often migratory), and lymphadenopathy, while two had pleural effusions and another developed myocarditits and pericarditis. Three of these developed anti-DNA antibodies associated with a low complement level. In four of their five children discontinuation of ethosuximide was followed by the disappearance of symptoms over a 5-13-month period; three, however, required corticosteriods for from 4 to 13 months to control their disease. One 14-year-old girl had persistent symptoms, and a renal biopsy performed because of a low C3 level showed a focal segmental glomerular nephritis; she had previously received phenyl hydantoin and ethosuximide for at least 2 years. Despite discontinuation of anticonvulsants and the use of corticosteriod therapy, 2 years later she still had active disease with renal involvement.
In general, antibodies to nuclear antigens in patients In the case report published in this issue a systemic lupus-like picture but without renal involvement developed in a boy receiving ethosuximide. However, he had had repeated streptococcal infections before the general illness and had also had a gastro-intestinal upset at onset of his joint symptoms. The fact that he made a complete recovery, so that at the 4-year follow-up he has no evidence of lupus or any antibodies, suggests that it was induced by ethosuximide.
